Healthcare • Biotechnology
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Company profile from EODHD, stored Nov 1, 2026.
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 6, 2026 | $3.3M | -57.8% | 100.0% | -$24.4M | -$23.0M |
| Mar 2026filed May 7, 2026 | $1.0M | -71.5% | — | -$24.9M | -$22.9M |
| Dec 2025filed Feb 25, 2026 | $6.2M | -88.5% | — | -$39.6M | -$37.3M |
| Sep 2025filed Nov 6, 2025 | $3.3M | -78.8% | — | -$37.6M | -$34.7M |
| Jun 2025filed Aug 7, 2025 | $7.9M | -47.8% | — | -$34.1M | -$30.5M |
| Mar 2025filed May 8, 2025 | $3.7M | -76.9% | — | -$44.7M | -$40.5M |
| Dec 2024filed Feb 26, 2025 | $54.2M | +257.1% | — | -$7.2M | -$2.1M |
| Sep 2024filed Nov 6, 2024 | $15.3M | +68.4% | — | -$48.4M | -$42.2M |
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 25, 2026 | $21.0M | -79.1% | 54.1% | -$145.8M | -$142.9M |
| Dec 2024filed Feb 26, 2025 | $100.6M | +3.6% | -84.9% | -$145.0M | -$119.0M |
| Dec 2023filed Feb 27, 2024 | $97.1M | -27.4% | 90.9% | -$151.7M | -$130.4M |
| Dec 2022filed Feb 28, 2023 | $133.6M | -35.5% | — | -$137.8M | -$133.3M |
| Dec 2021filed Feb 24, 2022 | $207.1M | +881.5% | — | -$37.4M | -$28.0M |
| Dec 2020filed Feb 25, 2021 | $21.1M | -0.6% | — | -$195.2M | -$183.0M |
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched ALEC. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
10,254,239 shares short
+4,107,207 shares (+66.8%) vs Sep 30, 2026
12.1% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
6,147,032 shares short
+42,229 shares (+0.7%) vs Sep 15, 2026
6.5% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
6,104,803 shares short
-60,424 shares (-1%) vs Aug 31, 2026
6.5% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
6,165,227 shares short
+263,646 shares (+4.5%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
5,901,581 shares short
+257,275 shares (+4.6%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
5,644,306 shares short
-20,627 shares (-0.4%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
See the recorded cash amounts and dates behind ALEC’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workSign in to see your position size
We’ll show you if ALEC is in your portfolio and how much it contributes.
Sign inLoading market dates
30 smart-money holders: institutions with a high Holder IQ
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: bearish
Last trade: sell 64 days ago
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 0
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
Stored recent-activity label: bearish. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
141 filers reported a long position in ALEC for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
51.9%
of the 91.2M shares 13-F filers reported
Moves vs Q1 2026
6 added1 trimmed
3 unchanged
Net shares held
+9.4%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | $20.1M · 10M shares | 10M | Unchanged |
| 2 | BlackRock, Inc. | $15.8M · 7.8M shares | 7.8M | +1.4% |
| 3 | ACADIAN ASSET MANAGEMENT LLC | $8.9M · 4.4M shares | 4.4M | +9.3% |
| 4 | Nantahala Capital Management, LLC | $8.7M · 4.3M shares | 4.3M | +53.3% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $8.1M · 4M shares | 4M | +9% |
| 6 | Kynam Capital Management, LP | $7.7M · 3.8M shares | 3.8M | +90.4% |
| 7 | Merck & Co., Inc. | $7.1M · 3.5M shares | 3.5M | Unchanged |
| 8 | BALYASNY ASSET MANAGEMENT L.P. | $6.5M · 3.2M shares | 3.2M | +10.6% |
| 9 | 683 Capital Management, LLC | $6.4M · 3.2M shares | 3.2M | Unchanged |
| 10 | D. E. Shaw & Co., Inc. | $5.9M · 3M shares | 3M | -11.2% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inHolders of more than 5% of ALEC file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Oct 26, 2026 | RA CAPITAL MANAGEMENT, L.P.13G · passive | 5.1% |
| Oct 23, 2026 | Deep Track Capital, LP13G · passive | 8.61% |
| Sep 18, 2026 | BIOTECHNOLOGY VALUE FUND L P13G · passive | 8.4% |
| May 14, 2026 | Polaris Venture Partners VI LP13G · passive · amended | 4.7%under 5% |
| Apr 27, 2026 | BlackRock, Inc.13G · passive | 5.2% |
| Mar 26, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
| Feb 9, 2024 | Alector Inc13G · passive · amended | — |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.